BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$330.01 USD
-14.59 (-4.23%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $329.77 -0.24 (-0.07%) 4:54 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for BioRad Laboratories, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 266.68 | 108.66 | 608.67 | 557.26 | 425.94 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 108.26 | 85.78 | 47.85 | 18.06 | 31.96 |
Net Cash From Operating Activities | 374.94 | 194.45 | 656.52 | 575.33 | 457.90 |
Property & Equipment | -156.47 | -112.62 | -120.75 | -98.85 | -98.40 |
Acquisition/ Disposition of Subsidiaries | 2.50 | -99.39 | -125.52 | -84.42 | -79.39 |
Investments | 174.18 | -994.21 | -538.17 | 119.60 | -39.92 |
Other Investing Activities | 0.00 | -1.38 | 0.00 | 3.41 | 8.82 |
Net Cash from Investing Activities | 20.21 | -1,207.59 | -784.44 | -60.25 | -208.89 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -410.24 | -198.12 | -29.37 | -79.81 | -11.06 |
Issuance (Repayment) of Debt | -0.47 | 1,185.71 | -3.02 | -426.94 | -0.64 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -14.94 | -14.02 | -23.04 | -16.30 | -11.06 |
Net Cash from Financing Activities | -425.65 | 973.58 | -55.43 | -523.04 | -22.76 |
Effect of Exchange Rate Changes | 0.32 | 2.98 | -12.64 | 12.43 | 2.24 |
Net Change In Cash & Equivalents | -30.18 | -36.59 | -195.98 | 4.46 | 228.49 |
Cash at Beginning of Period | 434.54 | 471.13 | 667.12 | 662.65 | 434.16 |
Cash at End of Period | 404.37 | 434.54 | 471.13 | 667.12 | 662.65 |
Diluted Net EPS | -21.82 | -121.79 | 140.56 | 126.20 | 58.27 |
Fiscal Year End for BioRad Laboratories, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 105.06 | 51.75 | 266.68 | 197.95 | 131.83 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 62.38 | 18.04 | 108.26 | 95.95 | 64.36 |
Net Cash From Operating Activities | 167.44 | 69.79 | 374.94 | 293.90 | 196.19 |
Property & Equipment | -82.37 | -40.15 | -156.47 | -114.33 | -70.33 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 2.50 | 0.00 | 0.00 |
Investments | 8.34 | -2.94 | 174.18 | 62.34 | 27.84 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -74.02 | -43.09 | 20.21 | -51.99 | -42.49 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -95.56 | 0.76 | -410.24 | -214.56 | -197.89 |
Issuance (Repayment) of Debt | -0.24 | -0.12 | -0.47 | -0.35 | -0.23 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.77 | -0.62 | -14.94 | -10.12 | -0.31 |
Net Cash from Financing Activities | -96.57 | 0.02 | -425.65 | -225.03 | -198.43 |
Effect of Exchange Rate Changes | 6.49 | 2.66 | 0.32 | 6.89 | 0.67 |
Net Change In Cash & Equivalents | 3.35 | 29.38 | -30.18 | 23.77 | -44.06 |
Cash at Beginning of Period | 404.37 | 404.37 | 434.54 | 434.54 | 434.54 |
Cash at End of Period | 407.72 | 433.75 | 404.37 | 458.32 | 390.48 |
Diluted Net EPS | -76.26 | 13.45 | 11.81 | 3.64 | -39.59 |